Kenya: Secures Alimatravir Manufacturing License for HIV PrEP

• Kenya's Universal Corporation Limited has received a royalty-free license from Merck to potentially manufacture generic alimatravir, an investigational HIV prevention pill.
• Alimatravir (MK-8527) is a once-monthly oral PrEP medicine currently undergoing Phase 3 clinical trials, with results expected next year.
• This agreement is unprecedented, marking the first time sub-Saharan African generic manufacturers are included early in a licensing arrangement for an investigational HIV prevention medicine.
• The initiative supports Kenya's national strategy to boost domestic pharmaceutical manufacturing, technology transfer, and health-sector capabilities.
• South Africa and Uganda are the other African nations included in this early licensing program, alongside four Indian companies.

This landmark agreement positions Kenya as one of three African nations poised to domestically produce a potentially groundbreaking HIV prevention medication for regional markets.

Kenya has secured a significant early licensing arrangement that could pave the way for domestic production of a novel HIV prevention medication. Universal Corporation Limited (UCL), a pharmaceutical manufacturer based in Kikuyu, Kenya, is among seven generic drugmakers globally to receive a royalty-free voluntary license from the global pharmaceutical company Merck. This license pertains to the manufacturing or supply of generic versions of alimatravir (MK-8527), an investigational once-monthly oral pre-exposure prophylaxis (PrEP) medicine, contingent upon its proven safety, efficacy, and subsequent regulatory approval.

This agreement marks a pivotal moment, as it is the first instance where generic manufacturers from sub-Saharan Africa have been included from the outset in a voluntary licensing arrangement for an investigational HIV prevention medicine. Alongside UCL, two other African companies—Aspen Pharmacare from South Africa and Quality Chemical Industries Limited from Uganda—have also been granted this Merck HIV prevention pill license, alongside four companies based in India. This places Kenya among a select group of African nations preparing for local production of a potential new HIV prevention option while Phase 3 studies for alimatravir are still underway, with results anticipated next year.

The alimatravir (MK-8527) voluntary license is a strategic move by Merck, allowing for broader access to the drug should it gain approval. The investigational medicine, designed to be taken once a month by individuals at risk of HIV infection, offers a potential alternative to daily oral prevention regimens. Its development and the early licensing initiative underscore a global effort to expand options for HIV prevention, particularly in regions with high prevalence.

This development is a substantial boost to Kenya's national agenda of expanding domestic pharmaceutical manufacturing and strengthening its health sector capabilities. Foreign Affairs Principal Secretary Korir Singoei highlighted that the agreement positions Kenya among three African countries set to manufacture the medicine for broader African markets, underscoring its regional significance. Medical Services Principal Secretary Dr. Ouma Oluga echoed this sentiment, linking the alimatravir manufacturing license directly to Kenya's commitment to local drug production, stating that it transforms the aspiration into a tangible reality.

The Kenyan government has actively pursued partnerships aimed at bolstering local pharmaceutical production, facilitating technology transfer, and enhancing domestic health-sector capabilities. The alimatravir agreement provides a concrete opportunity for Kenya's pharmaceutical sector to build essential manufacturing capacity around a medicine intended for markets where HIV prevention needs remain critically significant. Discussions held in September between Kenya's Ministry of Health and Merck specifically focused on key areas such as biotechnology, pharmaceutical manufacturing, skills development, and technology transfer, indicating a comprehensive approach to leveraging this partnership.

This initiative aligns with a broader strategy to ensure health security and self-sufficiency within the continent. By engaging in HIV PrEP pill manufacturing in Africa, nations like Kenya are taking proactive steps to control their pharmaceutical supply chains and improve access to vital medicines, reducing reliance on external sources and fostering economic growth within the local industry.

Alimatravir, as an investigational oral pre-exposure prophylaxis (PrEP) medicine, holds the promise of a once-monthly dosage, potentially offering a more convenient and adherence-friendly option for individuals at risk of HIV infection compared to current daily regimens. While the medicine is still undergoing Phase 3 clinical trials and awaits regulatory approval, its potential impact on global HIV prevention efforts, particularly in Africa, is considerable. The early licensing arrangement ensures that if approved, generic versions could be rapidly made available.

This move by Merck and the inclusion of African manufacturers also comes as Kenya continues to expand access to longer-acting HIV prevention technologies. In February, Kenya became the first country in East Africa to launch lenacapavir, an injectable HIV prevention medicine administered twice a year. This demonstrates Kenya's proactive stance in adopting and integrating advanced HIV prevention strategies into its public health framework.

The opportunity for Kenya local pharmaceutical manufacturing to produce alimatravir underscores a commitment to addressing the significant HIV prevention needs across African markets. By fostering local production capabilities, the agreement not only aims to improve access to this potential new therapy but also strengthens the continent's capacity to respond to public health challenges with domestically manufactured solutions.

This development signals a significant step in Kenya's domestic pharmaceutical manufacturing capabilities, particularly for HIV prevention. Lawyers and compliance officers in the pharmaceutical sector should monitor the regulatory approval process for alimatravir and be prepared to advise on future intellectual property licensing, manufacturing agreements, and public procurement related to this and similar initiatives aimed at local drug production and technology transfer.

Source: Original reporting